As bioequivalence (BE) assessments become increasingly reliant on advanced statistical methodologies, quantitative analysis, and model-informed development strategies, the ability to generate scientifically robust and regulatory-ready evidence is becoming more important than ever.
For organizations working at the intersection of bioequivalence, modeling and simulation, and regulatory analytics, FDA’s May 2026 revision of Statistical Approaches to Establishing Bioequivalence signals a continued shift toward more flexible, data-driven, and scientifically justified approaches to evidence generation.
The revised guidance replaces the 2001 version and introduces important updates aimed at modernizing the statistical framework for BE assessment.
Key additions and enhancements include:
🔹 Expanded recommendations for adaptive study designs, including sample size re-estimation and group sequential approaches for BE studies
🔹 Formal incorporation of estimands and intercurrent event strategies, improving clarity around treatment effects and regulatory interpretation
🔹 New recommendations for handling missing data, sensitivity analyses, and prespecified statistical assumptions to support robust, reproducible inference
🔹 Greater emphasis on replicate crossover designs and reference-scaled approaches for highly variable and narrow therapeutic index (NTI) drugs
🔹 Recognition of model-based bioequivalence approaches and other quantitative methods that may support future in silico and model-informed evidence generation
🔹 Expanded guidance for specialized scenarios, including in vitro BE, IVRT, IVPT, abuse-deterrent formulations, and multigroup studies
Collectively, these updates signal a shift from purely study-centric BE assessment toward frameworks that increasingly incorporate quantitative modeling, simulation, and risk-informed decision-making. Many of the revisions emphasize prospective planning and predefined analytical strategies, principles equally important in broader model-informed drug development programs. At InSilicoMinds, we see this evolution as particularly relevant for organizations leveraging modeling, simulation, and quantitative regulatory science. The guidance reinforces a principle that increasingly applies across modern drug development: generating evidence is no longer sufficient. Evidence must be scientifically defensible, statistically robust, and clearly aligned with regulatory expectations.
Link: https://www.linkedin.com/posts/insilicominds_fda-bioequivalence-activity-7475070158131089408-tS6A?utm_source=share&utm_medium=member_desktop&rcm=ACoAADwxO4EBoUDYrVD3Nd3qEIQA_HncV2kdfTM
